Sensorion Reports Full-Year 2022 Financial Results and Business Update

CTA filing for OTOF-GT planned for Q2 2023 Presented new preclinical data supporting continued progress of OTOF-GT, and potential for safe and efficient clinical translation of gene therapy

Related Keywords

Australia ,Paris ,France General ,France ,Dennis Riedl ,Nawal Ouzren ,Biolabs Pty ,David Lawrence ,Aniz Girach ,Institut Pasteur ,Matthew Cole Jessica Hodgson ,Hearing Institute Institut ,Boards Of Enterobiotix ,Good Laboratory Practice ,Research Development ,International Media Relations ,Cochlear Limited ,European Medicine Agency ,Good Laboratory Practices ,Communications Europe France ,Drug Administration ,European Commission ,Pasteur Institute ,Hearing Foundation ,European Medicines Agency ,Association For Research ,Consilium Strategic Communications ,Cisplatin Induced Ototoxicity ,Chief Financial Officer ,Independent Board ,Hearing Institute ,Chief Executive Officer ,Clinical Trial Application ,Hereditary Monogenic Hearing ,Non Human Primate ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Natural History Study ,Necker Enfants Malades ,Necker Hospital ,Pure Tone Audiometry ,Chief Medical Officer ,Chief Financial ,Enterobiotix Limited ,General Administrative ,Current Assets ,Sudden Sensorineural Hearing Loss ,Des Arm ,United Kingdom ,Investor Relations ,Strategic Communications ,Sue Stuart ,Sensorion ,Reports ,Bull ,Ear ,022 ,Financial ,Results ,Business ,Update ,